REGN Regeneron Pharmaceuticals Inc.

$327.69 -2.14%

557,950 Shares Traded
966,504 Average Volume (last 30 days)

as of March 22, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $17.02 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:14.35%
If Intiated One Month Ago, Shorts Have Realized a Return of:-1.44%
If Initiated Five Days ago, Shorts Have Realized a Return of:4.55%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bearish
50 Day Moving Average Indicator Bearish
52 Week High/Low Indicator Bearish

Short Stats

Short Percent to Float 2.23%
Short Interest2.37 million
Float106.18 million
Short Ratio1.91
Market Cap$35.29 billion
Market Maker ActivityDaily Short Volume


Your Daily Pharma Scoop: Omeros' Omidria, Titan Signs Agreement, Reata Announces Top-Line Results (SeekingAlpha)
U.S. Biotech/Pharma Sector Daily Observations Letter: March 21, 2018 (SeekingAlpha)
Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH) (PR Newswire)
Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease (PR Newswire)
Biotechs Approaching New Waters (SeekingAlpha)
Your Daily Pharma Scoop: Heron's HTX-011, Geron Update, Cidara Tumbles (SeekingAlpha)
3 Things In Biotech, March 19: Progenics, Denali, Regeneron. Gains All Around (SeekingAlpha)
BioSci Rounds Report: Unlocking The Value Of Ocular Therapeutix And Updating Solid Bioscience (SeekingAlpha)
Regeneron's Eylea successful in late-stage study in background retinopathy (SeekingAlpha)
EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial (PR Newswire)

Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 55.3%
Insider Percent1.4%

Earnings Stats

PE Ratio 23.71
Dividend Yield 0%
Peer EarningsEarnings Calendar


200 Day Moving Average $419.98
50 Day Moving Average $345.34
52 Week High $543.55
52 Week Low $313.53

Data provided for free by IEX. Questions? Read the FAQ